Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Sirna Therapeutics Inc patents


Recent patent applications related to Sirna Therapeutics Inc. Sirna Therapeutics Inc is listed as an Agent/Assignee. Note: Sirna Therapeutics Inc may have other listings under different names/spellings. We're not affiliated with Sirna Therapeutics Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "S" | Sirna Therapeutics Inc-related inventors


Short interfering nucleic acid (sina) compositions

The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of gene expression and/or activity, and/or modulate a gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (sina) molecules that are capable of mediating or that mediate rna interference (rnai) against target gene expression.. ... Sirna Therapeutics Inc

Rna interference mediated inhibition of prolyl hydroxylase domain 2 (phd2) gene expression using short interfering nucleic acid (sina)

The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of phd2 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (sina), short interfering rna (sirna), double-stranded rna (dsrna), micro-rna (mirna), and short hairpin rna (shrna) molecules that are capable of mediating or that mediate rna interference (rnai) against phd2 gene expression.. ... Sirna Therapeutics Inc

Single-stranded rnai agents containing an internal, non-nucleic acid spacer

The instant disclosure features single-stranded rna molecules comprising one or more internal, non-nucleotide spacers. A non-nucleotide spacer covalently links nucleotide portions of the molecule. ... Sirna Therapeutics Inc

Novel tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides

Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetragalnac ligands of formula (i), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.. . ... Sirna Therapeutics Inc

Novel low molecular weight cyclic amine containing cationic lipids for oligonucleotide delivery

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. ... Sirna Therapeutics Inc

Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)

The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of ctnnb1 gene expression and/or or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (sina), short interfering rna (sirna), double-stranded rna (dsrna), micro-rna (mirna), and short hairpin rna (shrna) molecules that are capable of mediating or that mediate rna interference (rnai) against ctnnb1 gene expression.. ... Sirna Therapeutics Inc

Novel low molecular weight cationic lipids for oligonucleotide delivery

The instant invention provides for novel catiome lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. ... Sirna Therapeutics Inc

Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)

The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (sina), short interfering rna (sirna), double-stranded rna (dsrna), micro-rna (mirna), and short hairpin rna (shrna) molecules capable of mediating rna interference (rnai) against target nucleic acid sequences. ... Sirna Therapeutics Inc

Novel tetragalnac and peptide containing conjugates and methods for delivery of oligonucleotides

Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetragalnac ligands of formula (i), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; 4) one or more peptides independently selected from table 3, which may be the same or different; and optionally, 5) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.. . ... Sirna Therapeutics Inc

Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)

The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (sina), short interfering rna (sirna), double-stranded rna (dsrna), micro-rna (mirna), and short hairpin rna (shrna) molecules capable of mediating rna interference (rnai) against target nucleic acid sequences. ... Sirna Therapeutics Inc

Novel tetragalnac containing conjugates and methods for delivery of oligonucleotides

Disclosed herein is a modular composition comprising 1) an oligonucleotide; 2) one or more tetragalnac ligands of formula (i), which may be the same or different; optionally, 3) one or more linkers, which may be the same or different; and optionally, 4) one or more targeting ligands, solubilizing agents, pharmacokinetics enhancing agents, lipids, and/or masking agents.. . ... Sirna Therapeutics Inc

Rna interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (sina)

The present invention concerns methods and reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to synthetic chemically modified small nucleic acid molecules, such as short interfering nucleic acid (sina), short interfering rna (sirna), double-stranded rna (dsrna), micro-rna (mirna), and short hairpin rna (shrna) molecules capable of mediating rna interference (rnai) against target nucleic acid sequences. ... Sirna Therapeutics Inc

Novel single chemical entities and methods for delivery of oligonucleotides

In an embodiment the instant invention discloses a modular composition comprising 1) an oligonucleotide; 2) one or more linkers, which may be the same or different, selected from table 1, wherein the linkers are attached to the oligonucleotide at the 2′-position of the ribose rings and/or the terminal 3′- and/or 5′-positions of the oligonucleotide; 3) optionally, one or more peptides, which may be the same or different, selected from seq id nos: 1-59, wherein the peptides are attached to the linkers; and optionally one or more lipids, solubilizing groups and/or targeting ligands attached to the oligonucleotide.. . ... Sirna Therapeutics Inc

Novel diester and triester based low molecular weight, biodegradeable cationic lipids for oligonucleotide delivery

The instant invention provides for novel cationic lipids of formula a that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. ... Sirna Therapeutics Inc

02/23/17 / #20170050917

Novel low molecular weight cationic lipids for oligonucleotide delivery

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. ... Sirna Therapeutics Inc

02/02/17 / #20170029824

Rna interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (ctnnb1) gene expression using short interfering nucleic acid (sina)

The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of ctnnb1 gene expression and/or activity, and/or modulate a beta-catenin gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic acid molecules, such as short interfering nucleic acid (sina), short interfering rna (sirna), double-stranded rna (dsrna), micro-rna (mirna), and short hairpin rna (shrna) molecules that are capable of mediating or that medium rna interference (rnai) against ctnnb1 gene expression.. ... Sirna Therapeutics Inc

01/26/17 / #20170022146

Novel low molecular weight cationic lipids for oligonucleotide delivery

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. ... Sirna Therapeutics Inc

01/19/17 / #20170015998

Low molecular weight cationic lipids for oligonucleotide delivery

The instant invention provides for novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. It is an object of the instant invention to provide a cationic lipid scaffold that demonstrates enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. ... Sirna Therapeutics Inc

01/05/17 / #20170001947

Diether based biodegradable cationic lipids for sirna delivery

Disclosed herein are novel cationic lipids that can be used in combination with other lipid components such as cholesterol and peg-lipids to form lipid nanoparticles with oligonucleotides. The cationic lipids can demonstrate enhanced efficacy along with lower liver toxicity as a result of lower lipid levels in the liver. ... Sirna Therapeutics Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Sirna Therapeutics Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Sirna Therapeutics Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###